위암 치료 시장 규모, 점유율 및 성장 분석 : 치료 유형별, 병기별, 최종사용자별, 유통경로별, 지역별 - 업계 예측(2026-2033년)

Global Stomach Cancer Treatment Market size was valued at USD 3.52 Billion in 2024 and is poised to grow from USD 3.83 Billion in 2025 to USD 7.52 Billion by 2033, growing at a CAGR of 8.82% during the forecast period (2026-2033).

The global stomach cancer treatment market is being reshaped by the increasing incidence and unmet clinical needs associated with the disease, which significantly impacts global morbidity and mortality. Surgical interventions, systemic therapies, targeted agents, immunotherapies, and supportive care play vital roles throughout various treatment phases. The market is particularly concentrated in East Asia, affecting aging populations, leading to national screening initiatives and heightened private investment. The evolution from traditional gastrectomy and chemotherapy to biomarker-driven therapies highlights the significance of genomic testing, allowing for targeted interventions like trastuzumab and checkpoint inhibitors. Enhanced reimbursement policies, growing oncology infrastructure, and demographic shifts in regions like China and Southeast Asia further stimulate demand while encouraging partnerships for diagnostics and therapeutics, ultimately driving revenue growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Stomach Cancer Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Stomach Cancer Treatment Market Segments Analysis

Global stomach cancer treatment market is segmented by treatment type, stage, end-user, distribution and region. Based on treatment type, the market is segmented into chemotherapy, targeted therapy, immunotherapy (nivolumab, pembrolizumab), surgery and radiation therapy. Based on stage, the market is segmented into early stage and advanced/metastatic. Based on end-user, the market is segmented into hospitals and cancer centers. Based on distribution, the market is segmented into hospital pharmacies and specialty pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Stomach Cancer Treatment Market

The Global Stomach Cancer Treatment market is driven by ongoing advancements in molecular diagnostics and targeted therapies, enabling healthcare professionals to accurately classify tumor sub-types and tailor treatment approaches for enhanced effectiveness and personalization. This growing adoption of innovative agents and combination therapies in oncology centers not only boosts physician confidence in prescribing intensive treatments but also stimulates investments in research and development. As clinical decision-making becomes more refined, manufacturers and providers are likely to focus on therapies that align with molecular profiling, thereby elevating the perceived value of treatments and improving patient outcomes, which ultimately expands the market.

Restraints in the Global Stomach Cancer Treatment Market

The Global Stomach Cancer Treatment market faces notable challenges due to the high costs associated with innovative therapies and complex treatment regimens. These expenses present significant financial burdens for both patients and healthcare systems, potentially hindering access to the full clinical benefits of these advanced treatments. Additionally, limited reimbursement policies and inconsistent coverage across different regions restrict healthcare providers' capacity to prescribe these high-cost agents. As a result, manufacturers encounter difficulties in achieving formulary placement. Institutions with budget constraints may opt for established, lower-cost alternatives, leading to delays in the adoption of newer treatment options.

Market Trends of the Global Stomach Cancer Treatment Market

The Global Stomach Cancer Treatment market is witnessing a significant trend towards precision oncology, where the integration of molecular profiling and biomarker-driven therapies is revolutionizing patient care. This shift enables clinicians to tailor treatments based on the unique biology of tumors, minimizing patients' exposure to ineffective drugs. Collaborative efforts between diagnostic test developers and pharmaceutical companies are setting the stage for a future rich in targeted therapies and companion diagnostics. As multidisciplinary teams increasingly utilize genomic data in clinical decision-making, the trend emphasizes personalized treatment approaches, stimulates investment in translational research, and enhances the therapeutic value by aligning treatment strategies with specific patient biology.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Stomach Cancer Treatment Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Chemotherapy
• Targeted Therapy
  • HER2 Inhibitors (Trastuzumab)
  • VEGF Inhibitors (Ramucirumab)
• Immunotherapy (Nivolumab, Pembrolizumab)
• Surgery
• Radiation Therapy

Global Stomach Cancer Treatment Market Size by Stage & CAGR (2026-2033)

• Market Overview
• Early Stage
• Advanced/Metastatic

Global Stomach Cancer Treatment Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Cancer Centers

Global Stomach Cancer Treatment Market Size by Distribution & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Specialty Pharmacies

Global Stomach Cancer Treatment Market Size & CAGR (2026-2033)

• North America (Treatment Type, Stage, End-User, Distribution)
  • US
  • Canada
• Europe (Treatment Type, Stage, End-User, Distribution)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Stage, End-User, Distribution)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Stage, End-User, Distribution)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Stage, End-User, Distribution)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Roche (Herceptin/Trastuzumab)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly (Cyramza/Ramucirumab)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (Opdivo)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (Keytruda)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (Enhertu - co-marketed)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo (Enhertu)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zymeworks
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seagen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zanosar (Pfizer)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Taiho Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ono Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Taisho Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akeso Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Innovent Biologics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BeiGene Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ZymeBio
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Corvus Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mirati Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MacroGenics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations